CoChat

Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism

Howe, Zachary, Naville-Cook, Chad, Cole, Derek · 2019 · Journal of Thrombosis and Thrombolysis

The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.

Abstract

This study examined potential differences in bleeding between apixaban and rivaroxaban, the most commonly utilized direct oral anticoagulants at the Richard L. Roudebush VA Medical Center. Additionally, the analysis included a comparison between observed and literature-reported bleeding rates. This retrospective chart review examined 452 (39%) Veterans receiving rivaroxaban and 716 (61%) Veterans receiving apixaban. Bleeding rates were expressed per 100 patient-years and the overall rates were analyzed as the primary analysis. Secondary objectives included comparisons based on indication and severity, as well as comparisons to literature-reported bleed rates, time to bleeding event, and location of the bleed. The analysis did not detect any statistically significant differences between apixaban and rivaroxaban in terms of overall, (ARR 0.90% per 100 patient-years, 95% CI - 0.58 to 2.38%, p > 0.05) major, (ARR 0.22% per 100 patient-years, 95% CI - 0.74 to 1.17%, p > 0.05) or non-major clinically relevant (ARR 0.35% per 100 patient-years, 95% CI - 0.57 to 1.27%, p > 0.05) bleeding. Observed bleeding for both rivaroxaban and apixaban in the Veteran population exceeded the rates reported by the literature when used for atrial fibrillation (1.96% vs. 0.15%, p < 0.05; 1.08% vs. 0.16%, p < 0.05) but the opposite was seen for long term venous thromboembolism (VTE) treatment (3.97% vs. 8.03%, p < 0.0001; 0.14% vs. 15.51%, p < 0.0001) or extended VTE prophylaxis (0.07% vs 5.98%, p < 0.…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11239-018-1770-7

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 15 references

Cited by

See all 8

Metadata

Authors
Howe, Z., Naville-Cook, C., & Cole, D.
Affiliations
  • Butler University (US)
  • Richard L. Roudebush VA Medical Center (US)
Corresponding author
Howe, Zachary
Venue
Journal of Thrombosis and Thrombolysis
Published
2018-11-17
Volume
47
Issue
2
Pages
280-286
ISSN
  • 0929-5305 (ISSN-L)
  • 1573-742X
OpenAlex
W2901182865
Cited by
8
References
16
Citations by year
2026: 2 · 2023: 1 · 2021: 2 · 2019: 3
FWCI
0.96
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Thrombosis and Thrombolysis (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Department of Veterans Affairs
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
apixaban, rivaroxaban, direct oral anticoagulants, bleeding risk, major bleeding, venous thromboembolism, atrial fibrillation, thromboprophylaxis, veterans, anticoagulant safety, veterans' health
MeSH terms
Rivaroxaban, Administration, Oral, Aged, Aged, 80 and over, Atrial Fibrillation, Blood Coagulation, Female, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Retrospective Studies, Risk Factors, Time Factors, United States, United States Department of Veterans Affairs, Treatment Outcome, Risk Assessment, Venous Thromboembolism, Veterans Health, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. https://app.cochat.ai/papers/10.1007/s11239-018-1770-7
The paper
Howe, Z., Naville-Cook, C., & Cole, D. (2019). Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-018-1770-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.